Licensing status

Publication and contact information


DNA methylation signatures in chronic lymphocytic leukemia (CLL)

DNA methylation signatures could help identify CLL subtypes and improve disease prognosis. In samples from 139 patients, epigenomic analysis revealed differences in CpG methylation patterns between naïve B cell-like and memory B cell-like CLLs and also identified a third subtype that is an intermediate between the molecular subtypes. In the patients, 20% of those with memory B cell-like disease, 43% of those with the intermediate disease phenotype and 100% of those with naïve B cell-like disease required treatment at 10 years. Next steps include validating the methylation signatures in additional patient cohorts.

SciBX 5(42); doi:10.1038/scibx.2012.1125
Published online Oct. 25, 2012

Patent application filed covering use in CLL; available for licensing from the Innovation Department at the Fundacio Clinic for Biomedical Research

Kulis, M. et al. Nat. Genet.; published online Oct. 14, 2012;
Contact: José I. Martin-Subero, University of Barcelona, Barcelona, Spain